Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Common Equity (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Common Equity for 16 consecutive years, with $143.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 6.83% to $143.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $143.5 million, a 6.83% decrease, with the full-year FY2025 number at $143.5 million, down 6.83% from a year prior.
  • Common Equity was $143.5 million for Q4 2025 at Anika Therapeutics, down from $146.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $290.1 million in Q3 2021 to a low of $143.5 million in Q4 2025.
  • A 5-year average of $232.8 million and a median of $272.3 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: grew 5.39% in 2021, then plummeted 33.5% in 2024.
  • Anika Therapeutics' Common Equity stood at $287.1 million in 2021, then fell by 0.53% to $285.6 million in 2022, then decreased by 25.67% to $212.3 million in 2023, then decreased by 27.45% to $154.0 million in 2024, then decreased by 6.83% to $143.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Common Equity are $143.5 million (Q4 2025), $146.8 million (Q3 2025), and $147.7 million (Q2 2025).